RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
18.1.2023 21:08:00 EET | Business Wire | Press release
RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117006135/en/
Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)
This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.
“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”
Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.
Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.”
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117006135/en/
Contact information
Michael Tiedemann
mtiedemann@revbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology21.4.2026 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance translational oncology research by integrating Turbine’s in silico Virtual Assays with its Tumor Organoid Assays based on HUB Organoid Technology. This collaboration establishes a connected workflow that enables researchers to move more efficiently from hypothesis to validation. Turbine’s Virtual Assays simulate biological response across thousands of biological samples and hundreds of drugs, generating predictive insights to identify and prioritize targets, therapies, and combinations. The predictions will be enhanced through the incorporation of multimodal and drug response data from hundreds of tumor organoid models at Crown Bioscience. Together, the companies create a closed-loop approach linking prediction with validation, improving predictive accuracy, reducing experimental burden, whil
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology21.4.2026 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance translational oncology research by integrating Turbine’s in silico Virtual Assays with its Tumor Organoid Assays based on HUB Organoid Technology. This collaboration establishes a connected workflow that enables researchers to move more efficiently from hypothesis to validation. Turbine’s Virtual Assays simulate biological response across thousands of biological samples and hundreds of drugs, generating predictive insights to identify and prioritize targets, therapies, and combinations. The predictions will be enhanced through the incorporation of multimodal and drug response data from hundreds of tumor organoid models at Crown Bioscience. Together, the companies create a closed-loop approach linking prediction with validation, improving predictive accuracy, reducing experimental burden, whil
Responding to Customer Demand, Starlink High-Speed Connectivity Now Available as an Aftermarket Option on the Cessna Citation Ascend; 560XL Series Achieves EASA Certification21.4.2026 15:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced at AERO Friedrichshafen the availability of Starlink highspeed connectivity as an aftermarket upgrade for the Cessna Citation Ascend, the newest aircraft in the bestselling Cessna Citation 560XL series, following the Federal Aviation Administration’s issuance of AeroMech’s Supplemental Type Certificate (STC). In addition, the Cessna Citation 560 XL fleet — including the XLS Gen 2, XLS+, XLS and Excel — has received European Union Aviation Safety Agency (EASA) certification for Starlink installation at Textron Aviation’s European service centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420017406/en/ Responding to customer demand, Starlink high-speed connectivity now available as an Aftermarket option on the Cessna Citation Ascend; 560XL series achieves EASA certification AeroMech’s STC utilizes Starlink’s high-speed internet technology connec
Adtran’s SDG router portfolio receives FCC conditional approval, supporting ongoing broadband expansion21.4.2026 15:00:00 EEST | Press release
Adtran today announced that its service delivery gateway (SDG) carrier-grade router portfolio has received conditional approval from the FCC’s Public Safety and Homeland Security Bureau, formally exempting the platforms from FCC Covered List restrictions through October 1, 2027. The decision places Adtran among the first router manufacturers to achieve this designation under the FCC’s national security review process. By ensuring continued access to Adtran’s SDG technology, the approval enables service providers to maintain deployment momentum, reduce operational risk and invest confidently in the long-term expansion of broadband networks while navigating evolving regulatory requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421651147/en/ Adtran’s SDG router portfolio has achieved FCC approval from Covered List restrictions through October 1, 2027. “Achieving this approval reflects the strength of our long‑stand
Redslim expands its global footprint into Latin America21.4.2026 15:00:00 EEST | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Latin America (LATAM) region, marking the next step in its growth strategy to support multinational brands and retailers across every major market. Following its recent expansion into APAC, this move reinforces Redslim’s momentum in building a truly global presence, reflecting growing demands from international clients for a trusted partner delivering reliable and AI-ready data and insights at scale. The expansion includes the appointment of Alejandro Merlo as Regional Director and Javier Gonzalez as Regional Manager for the region. Latin America represents a strong growth opportunity for global consumer brands, but also one of the most complex data environments. Rapid digital adoption and shifting consumer behaviours are driving demand for reliable market intelligence, while fragmented retailer structures and country-specific data landscapes make consis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom